The world’s largest trial of COVID-19 drugs has produced more good news: The anti-inflammatory drug tocilizumab cut the death risk of people hospitalized with the disease, reduced their need for a mechanical ventilator, and shortened time spent in the hospital. Used to treat rheumatoid arthritis and other autoimmune diseases, tocilizumab is a monoclonal antibody that blocks the protein that serves as receptor for interleukin-6 (IL-6), a signaling molecule in the immune system. That dampens the immune response, which is often overactive in late-stage COVID-19, causing serious disease and sometimes death. Soon after the pandemic started, physicians began to test tocilizumab against COVID-19 in small clinical trials. They were encouraged when Recovery showed in June 2020 that dexamethasone reduced COVID-19 deaths by up to one-third in hospitalized patients. That drug quickly became part of the standard of care.

“You might think of corticosteroids like dexamethasone as a very sort of shotgun approach,” to turning down the immune system, Peter Horby, one of Recovery’s principal investigators, said at today’s press conference. “We’re now looking at drugs that are very targeted.”

In the trial, 2022 patients were randomly allocated to receive tocilizumab and compared with 2094 others randomized to receive usual care; 82% of the patients also received dexamethasone. After 28 days, 596 patients in the tocilizumab group had died, compared with 694 in the control group, a reduction of the mortality rate from 33% to 29%. That means on average 25 patients have to be treated with the drug to save one life.

The drug comes at a steeper price than dexamethasone, however: about £500 per treatment course in the United Kingdom, versus £5 for the steroid. “This is going to be one more tool for wealthy countries to add to the mix, but not something that’s going to be widely available for the rest of the world,” Jha says. But that can change, Horby says: “I would hope that there will be a lot of work going on behind the scenes now and in the next few months, to see what can be done to make sure … that this drug does become available to everyone, not just to those in rich countries.”

Tocilizumab is not the only available IL-6 inhibitor. Another inhibitor called sarilumab showed a similar effect in the REMAP-CAP trial, but results from two large, completed trials of that drug are yet to be reported. “Publication of results from those trials is now essential to assess whether alternative [interleukin-6] antagonists to tocilizumab are effective,” the Recovery investigators write in their preprint.

The largest trial of COVID-19 therapeutics in the world, Recovery has so far enrolled more than 36,000 patients at about 170 U.K. clinics. In addition to identifying two successful drugs, it helped rule out several others, including the antimalarial hydroxychloroquine, the HIV drug combination lopinavir/ritonavir, and azithromycin, an antibiotic. The trial is still testing aspirin, an anti-inflammatory drug named colchicine, an antibody cocktail from drug company Regeneron, and baricitinib, another drug used to treat rheumatoid arthritis.

For more kindly go through: Biomedical Research

Biomedical Research accepts direct submissions from authors: Attach your word file with e-mail and send it to biomedres@emedsci.com

Media Contact:

Joel James

Managing Editor

Biomedical Research